Early experience of COVID-19 vaccination in adults with systemic rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey.
Early experience of COVID-19 vaccination in adults with systemic rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey.
复制标题
DOI：
10.1136/rmdopen-2021-001814
复制
发表时间：
2021-09
期刊：
影响因子：
6.2
通讯作者：
Sparks JA
中科院分区：
文献类型：
--
作者：
Sattui SE;Liew JW;Kennedy K;Sirotich E;Putman M;Moni TT;Akpabio A;Alpízar-Rodríguez D;Berenbaum F;Bulina I;Conway R;Singh AD;Duff E;Durrant KL;Gheita TA;Hill CL;Howard RA;Hoyer BF;Hsieh E;El Kibbi L;Kilian A;Kim AH;Liew DFL;Lo C;Miller B;Mingolla S;Nudel M;Palmerlee CA;Singh JA;Singh N;Ugarte-Gil MF;Wallace J;Young KJ;Bhana S;Costello W;Grainger R;Machado PM;Robinson PC;Sufka P;Wallace ZS;Yazdany J;Harrison C;Larché M;Levine M;Foster G;Thabane L;Rider LG;Hausmann JS;Simard JF;Sparks JA
我们描述了接种新冠肺炎疫苗的成人系统性风湿病患者的早期经历。从2021年4月2日至4月30日，我们对接受新冠肺炎疫苗接种的系统性风湿病成人进行了一项在线的国际调查。我们收集了患者报告的关于临床医生在接种疫苗前后停止服用抗风湿病药物(DMARD)的沟通、信念和意图的数据，以及接种疫苗后患者报告的不良事件。我们分析了2,860名接受新冠肺炎疫苗接种的成人系统性风湿病患者(平均年龄55.3岁，女性86.7%，白人86.3%)。新冠肺炎疫苗种类依次为辉瑞生物科技(53.2%)、牛津/阿斯利康(22.6%)、莫德纳(21.3%)、扬森/强生(1.7%)和其他(1.2%)。最常见的风湿性疾病是类风湿性关节炎(42.3%)，81.2%的受访者服用DMARD。大多数人(81.9%)报告与临床医生就接种疫苗进行了沟通。大多数人(66.9%)愿意暂时停止使用DMARDS以提高疫苗效果，尽管许多人(44.3%)担心风湿病发作。接种疫苗后，报告的患者最多的不良事件是疲倦/嗜睡(33.4%)、头痛(27.7%)、肌肉/关节疼痛(22.8%)和发烧/发冷(19.9%)。需要更换药物的风湿性疾病发作发生率为4.6%。在接受新冠肺炎疫苗接种的系统性风湿病成人中，患者报告的不良事件与普通人群报告的不良事件典型。大多数患者愿意暂时停止使用DMARDS以提高疫苗效力。风湿性疾病发作需要药物治疗的频率相对较低，这一点令人放心。
We describe the early experiences of adults with systemic rheumatic disease who received the COVID-19 vaccine. From 2 April to 30 April 2021, we conducted an online, international survey of adults with systemic rheumatic disease who received COVID-19 vaccination. We collected patient-reported data on clinician communication, beliefs and intent about discontinuing disease-modifying antirheumatic drugs (DMARDs) around the time of vaccination, and patient-reported adverse events after vaccination. We analysed 2860 adults with systemic rheumatic diseases who received COVID-19 vaccination (mean age 55.3 years, 86.7% female, 86.3% white). Types of COVID-19 vaccines were Pfizer-BioNTech (53.2%), Oxford/AstraZeneca (22.6%), Moderna (21.3%), Janssen/Johnson & Johnson (1.7%) and others (1.2%). The most common rheumatic disease was rheumatoid arthritis (42.3%), and 81.2% of respondents were on a DMARD. The majority (81.9%) reported communicating with clinicians about vaccination. Most (66.9%) were willing to temporarily discontinue DMARDs to improve vaccine efficacy, although many (44.3%) were concerned about rheumatic disease flares. After vaccination, the most reported patient-reported adverse events were fatigue/somnolence (33.4%), headache (27.7%), muscle/joint pains (22.8%) and fever/chills (19.9%). Rheumatic disease flares that required medication changes occurred in 4.6%. Among adults with systemic rheumatic disease who received COVID-19 vaccination, patient-reported adverse events were typical of those reported in the general population. Most patients were willing to temporarily discontinue DMARDs to improve vaccine efficacy. The relatively low frequency of rheumatic disease flare requiring medications was reassuring.
登录
查看更多内容
影响因子：
6.2
作者：
Glintborg B;Jensen DV;Engel S;Terslev L;Pfeiffer Jensen M;Hendricks O;Ostergaard M;Horskjær Rasmussen S;Adelsten T;Colic A;Danebod K;Kildemand M;Loft AG;Munk HL;Pedersen JK;Østgård RD;Møller Sørensen C;Krogh NS;Agerbo J;Ziegler C;Hetland M
通讯作者：
Hetland M
影响因子：
27.4
作者：
Park, Jin Kyun;Lee, Yun Jong;Lee, Eun Bong
通讯作者：
Lee, Eun Bong
影响因子：
6.2
作者：
Schulze-Koops H;Specker C;Skapenko A
通讯作者：
Skapenko A
影响因子：
5
作者：
Lawson EF;Trupin L;Yelin EH;Yazdany J
通讯作者：
Yazdany J
影响因子：
13.8
作者：
Thompson HS;Manning M;Mitchell J;Kim S;Harper FWK;Cresswell S;Johns K;Pal S;Dowe B;Tariq M;Sayed N;Saigh LM;Rutledge L;Lipscomb C;Lilly JY;Gustine H;Sanders A;Landry M;Marks B
通讯作者：
Marks B